Literature DB >> 23898115

Reduction in γ-glutamyl hydrolase expression is associated with response to uracil and tegafur/leucovorin chemotherapy in patients with colorectal cancer.

Sotaro Sadahiro1, Toshiyuki Suzuki, Akira Tanaka, Kazutake Okada, Akemi Kamijo, Hideki Nagase, Junji Uchida.   

Abstract

To identify the genes and clinical parameters associated with efficacy of uracil and tegafur/leucovorin (UFT/LV) chemotherapy in colorectal cancer (CRC), we compared the levels of reduced folate in tumors between patients receiving LV and those not receiving LV (study I), and explored the changes in the expression levels of 14 genes after two weeks of UFT/LV chemotherapy in 73 patients with CRC (study II). In study I, the reduced folate levels after LV administration were approximately 3-fold higher than those without LV administration in patients with right-sided tumors or aged >75 years old (p=0.019). In study II, the reduction in γ-glutamyl hydrolase (GGH) expression in responders and in patients with right-sided tumors or aged >75 years old was significantly greater than that in non-responders (p<0.001) and in other patients, respectively (p=0.003). Increase of reduced folate and reduction in GGH expression were associated with response to UFT/LV chemotherapy in patients with right-sided tumors or aged >75 years old.

Entities:  

Keywords:  Colorectal cancer; folate; gene expression; leucovorin; tegafur-uracil; γ-glutamyl hydrolase (GGH)

Mesh:

Substances:

Year:  2013        PMID: 23898115

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  1 in total

1.  Gene expression levels of gamma-glutamyl hydrolase in tumor tissues may be a useful biomarker for the proper use of S-1 and tegafur-uracil/leucovorin in preoperative chemoradiotherapy for patients with rectal cancer.

Authors:  Sotaro Sadahiro; T Suzuki; A Tanaka; K Okada; G Saito; H Miyakita; T Ogimi; H Nagase
Journal:  Cancer Chemother Pharmacol       Date:  2017-04-17       Impact factor: 3.333

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.